There may be a path through the CRISPR patent jungle, but there are many obstacles still in the way, say European academics Timo Minssen, Esther van Zimmeren and Jakob Wested.
The 12th annual BIO-Europe Spring conference, to be held in Amsterdam, the Netherlands on March 12 to 14, 2018, will allow key players in the biotech industry to come together, as Catherine Moreno Finan reports.
While the impact of the European Medicines Agency’s relocation from London to Amsterdam is unknown, industry and government will try to ensure that the UK remains at the forefront of medicines regulation, says Rachel Bradley of Penningtons Manches.
BACIT, a former fund of funds, has combined with life sciences investment company Syncona to form a new investment vehicle using the latter’s name. LSIPR speaks to Arabella Cecil, one of the co-founders of BACIT, about the new company’s vision.
Thomas Kirkbak, chief IP litigation specialist at Danish company Lundbeck, faces challenges on several fronts, as he explains to LSIPR.
Pharmaceutical company UCB injects a significant amount of revenue into R&D, but it is mindful of the risks attached to drug investment. Global head of IP Stéphane Drouin explains more in an interview with LSIPR.
Richard Henderson, an award-winning scientist based in Cambridge, UK, is seeking to make his next important discovery in the field of biological electron microscopy, as LSIPR finds out.
From the Unified Patent Court to life sciences industrial strategy, there are many issues for Sean Dennehey to contend with as deputy CEO of the UK Intellectual Property Office. He talks to LSIPR about how he managed.
As CEO of the UK BioIndustry Association, Steve Bates works closely with industry and government and, by 2025, he wants the UK to become home to the third biggest global biotech cluster, as he explains to LSIPR.
Tim Haines was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.